Home › NDC Lookup › RxCUI directory › RxCUI 2265683

Voxelotor 500 MG Oral Tablet — RxCUI 2265683

RxNorm drug concept · Semantic clinical drug
RxCUI 2265683 Semantic clinical drug · SCD ● Current RxNorm concept 3 FDA products 5 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2265683
Official nameVoxelotor 500 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped3
Package NDCs mapped5
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Voxelotor: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Voxelotor, sold as Oxbryta, treats sickle cell disease in adults and children 4 years and older. It helps keep hemoglobin from clumping, which is what bends red blood cells into si...
  • Take your tablet by mouth once a day, with or without food. Swallow it whole, and don't cut, crush, or chew it. If you miss a dose, just pick up again the next day. Your prescriber...
  • The most common ones are headache, diarrhea, belly pain, nausea, rash, and fever. Many people have mild versions. Let your doctor know if they bother you or don't go away.
  • Get help quickly if you develop a widespread rash, hives, trouble breathing, or swelling of your face. These can be signs of a serious allergic reaction. Don't take it again if you...
📖 Read our full Voxelotor guide →

🕸️ Concept Web — How Voxelotor 500 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Voxelotor 500 MG Oral Tablet RxCUI 2265683

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Voxelotor 2265678
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Oxbryta 2265684
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Voxelotor Oral Tablet 2265682
    • Voxelotor Oral Product 2265680
    • Voxelotor Pill 2265681
    • Voxelotor Oral Tablet [Oxbryta] 2265686
    • Oxbryta Oral Product 2265687
    • Oxbryta Pill 2265688
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Voxelotor 500 MG SCDC · 2265679
  • Voxelotor Oral Tablet SCDF · 2265682
  • Voxelotor Oral Product SCDG · 2265680
  • Voxelotor Pill SCDG · 2265681

Brand-Name Concepts

  • Voxelotor 500 MG Oral Tablet [Oxbryta] SBD · 2265689
  • Voxelotor 500 MG [Oxbryta] SBDC · 2265685
  • Voxelotor Oral Tablet [Oxbryta] SBDF · 2265686
  • Oxbryta Oral Product SBDG · 2265687
  • Oxbryta Pill SBDG · 2265688
  • Oxbryta BN · 2265684

📦 FDA Products & Package NDCs

3 products · 5 package NDCs
5 package NDCs map to RxCUI 2265683 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
72786-0101-01 90 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (72786-101-01) OXBRYTA Global Blood Therapeutics, Inc, A subsidiary of Pfizer Inc. 2019-11-25
72786-0102-02 60 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (72786-102-02) OXBRYTA Global Blood Therapeutics, Inc, A subsidiary of Pfizer Inc. 2022-10-14
72786-0102-03 90 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (72786-102-03) OXBRYTA Global Blood Therapeutics, Inc, A subsidiary of Pfizer Inc. 2022-10-14
72786-0111-02 60 TABLET, FOR SUSPENSION in 1 BOTTLE, PLASTIC (72786-111-02... OXBRYTA Global Blood Therapeutics, Inc, A subsidiary of Pfizer Inc. 2021-12-17
72786-0111-03 90 TABLET, FOR SUSPENSION in 1 BOTTLE, PLASTIC (72786-111-03... OXBRYTA Global Blood Therapeutics, Inc, A subsidiary of Pfizer Inc. 2021-12-17
Observed labelers: Global Blood Therapeutics, Inc, A subsidiary of Pfizer Inc. (5) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.